rawfin.tv
Regeneron's Fianlimab Phase 3 Trial Fails to Meet Primary Endpoint
MarketsstocksAI Generated

Regeneron's Fianlimab Phase 3 Trial Fails to Meet Primary Endpoint

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Regeneron announced that its Phase 3 trial for fianlimab did not achieve statistical significance for progression-free survival. This outcome represents a setback for the drug's development and potential market entry in the pharmaceutical sector.

biotechnologyclinical-trialsdrug-development

Related Articles

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

stocks
S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks